Metastatic and histologic presentations in unknown primary cancer.

Abstract:

:The patient with metastatic adeno- or undifferentiated carcinoma who presents with a cryptic primary is subjected to an extensive diagnostic search. These efforts apparently stem from the following assumptions: 1). The ultimately proven primary sites in such patients will occur with the same frequency as the most commonly occurring carcinomas (i.e., lung, breast, colon, prostate, etc.); and 2). Metastatic patterns and histologies seen at diagnosis are the same as for patients presenting with these more common tumors. Our data contradict these assumptions. For example, the most commonly occurring unknown primary was pancreas. Rarely occurring primaries included breast and prostate. Lung cancer was observed frequently, but the presentation was atypical because of the large proportion of female patients. In addition, the metastatic patterns at diagnosis were unusual for many of the ultimately proven primary sites. In an attempt to deal with these contradictions, a method to search for new relationships between primary site and metastatic-histologic presentations was employed. This method succeeded in placing the location of the primary cancer to above or below the diaphragm in 80% of the patients studied retrospectively. Tested prospectively in a small group of patients, the method appears to be clincally useful. Finally, in this study we have made the diagnosis, antemortem, of the primary cancer site (PCS) in only 30 of 264 patients. The failure to find the primary site, dispite extensive radiologic work-up, was disappointing to the authors, and emphasizes the difficulty of finding PCS antemortem. In our study pancreas and lung appear to be most common cryptic primary sites.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Nystrom JS,Weiner JM,Heffelfinger-Juttner J,Irwin LE,Bateman JR,Wolf RM

subject

Has Abstract

pub_date

1977-03-01 00:00:00

pages

53-8

issue

1

eissn

0093-7754

issn

1532-8708

journal_volume

4

pub_type

杂志文章
  • Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

    abstract::Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Holmes FA

    更新日期:1996-10-01 00:00:00

  • Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review.

    abstract::Follicular lymphoma is a low-grade, indolent non-Hodgkin's lymphoma characterized by the presence of the t(14;18) translocation. The detection of this translocation using polymerase chain reaction techniques has been increasingly studied. However, the diagnostic and prognostic value of detecting t(14;18) rearrangement...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bordeleau L,Berinstein NL

    更新日期:2000-12-01 00:00:00

  • Vinorelbine (Navelbine) in the treatment of breast cancer: a summary.

    abstract::One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Abeloff MD

    更新日期:1995-04-01 00:00:00

  • Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?

    abstract::First-line therapy for men with metastatic or recurrent prostate cancer following definitive local therapy is medical or surgical castration. Though effective initially in most patients, the majority of tumors develop castration resistance, necessitating the addition of further therapy. The historic treatment paradigm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.04.015

    authors: Hoffman-Censits J,Fu M

    更新日期:2013-06-01 00:00:00

  • Kinetic concepts in the systemic drug therapy of breast cancer.

    abstract::Optimal management of cancer today requires a thorough and up-to-date understanding of cancer cell kinetics and biochemistry. This report reviews the history and current standards in these fields and how they affect the contemporary approach to breast cancer management. Also outlined are recommended avenues for future...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Norton L

    更新日期:1999-02-01 00:00:00

  • The role of music therapy in palliative medicine and supportive care.

    abstract::This paper is designed to provide an introduction to music therapy in the continuum of cancer care. The value and use of music therapy during diagnosis and treatment, palliation, hospice, actively dying, and bereavement have been well documented. The music therapy process will be identified, research will be shared, a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2011.03.010

    authors: Gallagher LM

    更新日期:2011-06-01 00:00:00

  • Palliative radiation therapy.

    abstract::Radiation is an effective modality to aid in symptom management of patients with metastatic disease. The type and duration of treatment depends on the Karnofsky performance status (KPS) of the patient and type and status of the cancer. Abbreviated treatment regimens may be favored in this patient population. They prov...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.11.013

    authors: Konski A,Feigenberg S,Chow E

    更新日期:2005-04-01 00:00:00

  • Recent developments in breast cancer therapy.

    abstract::Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hortobagyi GN,Hung MC,Buzdar AU

    更新日期:1999-08-01 00:00:00

  • Inflammatory breast cancer: patient advocate view.

    abstract::Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis. While controversy exists regarding the actual incidence of the disease, there is agreement that IBC causes a disproportionate number of breast cancer deaths. Those with typical IBC symptoms face a h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.11.011

    authors: Mason G,Johnson O

    更新日期:2008-02-01 00:00:00

  • Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.

    abstract::Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). This rate of response is seen in patients with poor prognostic factors such as liver metastases and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Trudeau ME

    更新日期:1999-06-01 00:00:00

  • Spirituality and healing.

    abstract::Spirituality can exert a tremendous impact on ones health and promote recovery from trauma and illness, including cancer. Throughout the history of mankind, spirituality and religion have played a major role in healing a variety of physical and mental illnesses. Cancer is one of the most devastating illnesses, as it a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2004.11.017

    authors: Torosian MH,Biddle VR

    更新日期:2005-04-01 00:00:00

  • Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

    abstract::The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Young RC

    更新日期:2000-06-01 00:00:00

  • Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

    更新日期:1995-08-01 00:00:00

  • Interferons and their stimulated genes in the tumor microenvironment.

    abstract::Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced by the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathwa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.02.002

    authors: Cheon H,Borden EC,Stark GR

    更新日期:2014-04-01 00:00:00

  • Novel strategies for the early detection and prevention of lung cancer.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.02.009

    authors: Wardwell NR,Massion PP

    更新日期:2005-06-01 00:00:00

  • Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection.

    abstract::The human gammaherpesvirus family includes Epstein-Barr virus (EBV) and human herpesvirus (HHV)-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV). In human immunodeficiency virus (HIV)-infected patients, both EBV and KSHV have been implicated in the development of a wide range of tumors. KSHV-associated di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.026

    authors: Pinzone MR,Berretta M,Cacopardo B,Nunnari G

    更新日期:2015-04-01 00:00:00

  • Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

    abstract::Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

    更新日期:1988-02-01 00:00:00

  • Prognostic factors in renal carcinoma.

    abstract::Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rini BI,Vogelzang NJ

    更新日期:2000-04-01 00:00:00

  • Factors influencing quality of life in cancer patients: anemia and fatigue.

    abstract::Anemia is a multi-symptom syndrome involving both physical and emotional problems that can be evaluated for their impact on quality of life. Fatigue is the cardinal symptom of anemia, reported by three of four cancer patients using the general version of the Functional Assessment of Cancer Therapy (FACT-G) questionnai...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Cella D

    更新日期:1998-06-01 00:00:00

  • Unraveling biologic therapy for Bcl-2-expressing malignancies.

    abstract::Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Most treatments for such cancer involve chemotherapy to induce the apoptotic process. While these therapies often result in disease control for periods of time, failure to initiate apoptosis as a result of acq...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.10.014

    authors: Cotter FE

    更新日期:2004-12-01 00:00:00

  • Practical considerations in the evaluation and management of adrenocortical cancer.

    abstract::Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.10.011

    authors: Balasubramaniam S,Fojo T

    更新日期:2010-12-01 00:00:00

  • Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.

    abstract::The evaluation of the activity of new drugs against small cell lung cancer (SCLC) is discussed and the results with gemcitabine are presented. Gemcitabine has activity against untreated SCLC. Preliminary results from an ongoing study also indicate activity in so-called resistant SCLC. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Postmus PE,Schramel FM,Smit EF

    更新日期:1998-08-01 00:00:00

  • Preliminary experience with paclitaxel in advanced bladder cancer.

    abstract::In a phase II Eastern Cooperative Oncology Group trial, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was administered to 26 patients with advanced urothelial cancer who had not received prior systemic chemotherapy. Paclitaxel was given at a dose of 250 mg/m2 by 24-hour continuous infusi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Roth BJ

    更新日期:1995-06-01 00:00:00

  • Recommendations of follow-up after treatment of germ cell tumors.

    abstract::Patients diagnosed with germ cell tumors (GCT) are relatively young, and most are rendered disease-free by primary treatment. Also, second-line therapies in nearly all instances are potentially curative. Therefore, the schedule and modalities of follow-up testing are important issues in detecting recurrence of GCT and...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00098-8

    authors: Kondagunta GV,Sheinfeld J,Motzer RJ

    更新日期:2003-06-01 00:00:00

  • A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome.

    abstract::From February 1985 to June 1993, 173 consecutive, previously untreated patients with small cell lung cancer received individualized treatment tailored to disease extent. Almost all patients (14 of 16) with stage I and II disease and 30 patients with operable stage III disease were submitted to surgery preceded or foll...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Santoro A,Parra HS,Bidoli P,Angelidou M,Cataldo I,Salvini P,Valagussa P,Milani F,Ravasi G,Bonadonna G

    更新日期:1995-02-01 00:00:00

  • Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

    abstract::The purpose of this study is to evaluate the efficacy and safety of a biweekly neoadjuvant docetaxel/gemcitabine regimen in patients with histologically confirmed stage II and III breast cancer. In addition, a cDNA microarray study attempted to correlate pretreatment gene-expression profile with clinical and pathologi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2004.03.025

    authors: Estévez LG,Sánchez-Rovira P,Dómine M,León A,Calvo I,Jaén A,Casado V,Rubio G,Daz M,Miró C,Lobo F

    更新日期:2004-04-01 00:00:00

  • Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.

    abstract::Despite cures in early stage (IA-IIB) non-small cell lung cancer (NSCLC), the 5-year survival rate is only 36%-73%. Surgical resection via lobectomy is the treatment of choice in early-stage NSCLC, with the goal being complete anatomic resection of the tumor and mediastinal lymph node evaluation. Newer technologies, i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.12.011

    authors: Padda SK,Burt BM,Trakul N,Wakelee HA

    更新日期:2014-02-01 00:00:00

  • Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer.

    abstract::The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.08.006

    authors: Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

    更新日期:2012-10-01 00:00:00

  • Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.

    abstract::The purpose of this study was to evaluate the combination of gemcitabine, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. Previously untreated patients with stage IIIB or IV non-small cell lung cancer were enrolled into this trial. Sixty-nine patients from the phase II portion and eig...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Burris HA 3rd,Hainsworth JD,Erland JB,Morrissey LH,Kalman LA,Hon JK,Scullin DC Jr,Smith SW,Greco FA

    更新日期:2000-02-01 00:00:00

  • Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.

    abstract::Breast cancer patients undergoing therapeutic regimens of high-dose chemotherapy (HDCT) with circulating progenitor cell support often develop anemia. As a general consideration in the transplantation setting, red blood cell transfusions are normally required in patients who have passed the myeloablative phase after H...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.33529

    authors: Danova M,Ferrari S

    更新日期:2002-06-01 00:00:00